Related Experiment Video

Updated: Jun 6, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Chloroethyl urea derivatives block tumour growth and thioredoxin-1 nuclear translocation

Alexandre Patenaude1, Jessica S Fortin, Réna Deschenes

  • 1Unité de Biotechnologie et de Bioingénierie, CHUQ, Hôpital Saint-François d'Assise, Université Laval, Québec, QC, Canada.

Canadian Journal of Physiology and Pharmacology
|November 16, 2010
PubMed

Insights

Aryl chloroethyl ureas (CEUs) are novel anticancer agents that target thioredoxin-1 (TRX1). CEU-025 blocks TRX1 nuclear translocation, unexpectedly protecting cells from cisplatin, indicating a unique mechanism of action.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Aryl chloroethyl ureas (CEUs) are a class of protein alkylating agents with demonstrated anticancer properties.
  • Thioredoxin-1 (TRX1) is a crucial protein involved in redox homeostasis and cellular signaling pathways.

Purpose of the Study:

  • To investigate the molecular mechanism of action of CEU derivatives, specifically CEU-025 and CEU-027.
  • To elucidate the interaction between CEUs and TRX1, and its impact on TRX1 function and cellular response.

Main Methods:

  • Utilized 14C-labeled CEU derivatives (CEU-025, CEU-027) to study covalent binding to TRX1.
  • Employed site-directed mutagenesis and diamide competition assays to identify TRX1 targets.
  • Assessed the effect of CEU-025 on TRX1 nuclear translocation in human cancer cells.
  • Investigated the role of TRX1 in CEU-025 cytotoxicity using gene overexpression and siRNA suppression.

Main Results:

  • CEU-025 and CEU-027 were found to covalently bind to TRX1, with minimal impact on its disulfide-reducing activity.
  • TRX1 cysteinyl residues were not identified as the primary targets of CEU binding.
  • CEU-025 inhibited the nuclear translocation of TRX1, both spontaneously and when induced by cisplatin.
  • Pretreatment with CEU-025 protected cancer cells against cisplatin-induced cytotoxicity.
  • Modulation of TRX1 levels affected CEU-025 cytotoxicity, suggesting TRX1's involvement in the drug's action.

Conclusions:

  • CEU-025 and CEU-027 exert anticancer effects via a novel mechanism involving the intracellular localization of TRX1.
  • The findings highlight the critical role of TRX1's subcellular distribution in mediating the cytotoxic activity of these CEU compounds.
  • Further research into TRX1 modulation could offer new therapeutic strategies in cancer treatment.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...